(₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
---|---|---|---|---|---|
Total Income | 77.23 | 73.27 | 60.65 | 5.4% | 27.3% |
Total Expenses | 71.16 | 67.70 | 48.02 | 5.1% | 48.2% |
Profit Before Tax | 6.07 | 5.56 | 14.27 | 9.2% | -57.5% |
Tax | 0.71 | 0.97 | 0.68 | -26.8% | 4.4% |
Profit After Tax | 5.36 | 4.59 | 13.59 | 16.8% | -60.6% |
Earnings Per Share | 1.00 | 0.80 | 13.20 | 25.0% | -92.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Balaxi Pharmaceuticals Ltd is a well-established company in the pharmaceutical industry. The company specializes in manufacturing and distributing pharmaceutical products, with a focus on generic medicines. Balaxi Pharmaceuticals operates in both domestic and international markets, aiming to provide affordable healthcare solutions. The company is known for its robust distribution network and a diverse portfolio of products. As of the latest updates, there are no specific major developments provided, but the company continues to maintain a strong presence in its sector.
In the third quarter of fiscal year 2025 (Q3FY25), Balaxi Pharmaceuticals Ltd reported a total income of ₹77.23 crores. This represents a sequential quarter-over-quarter (QoQ) increase of 5.4% from ₹73.27 crores in the second quarter of fiscal year 2025 (Q2FY25). On a year-over-year (YoY) basis, the total income grew by 27.3% compared to ₹60.65 crores in the third quarter of fiscal year 2024 (Q3FY24). This growth in revenue indicates the company's strong performance in expanding its income streams over the past year.
The profit before tax for Q3FY25 stood at ₹6.07 crores, marking a 9.2% QoQ increase from ₹5.56 crores in Q2FY25. However, when compared to the same quarter in the previous year (Q3FY24), there is a significant drop of 57.5% from ₹14.27 crores. After accounting for taxes, the profit after tax for Q3FY25 was ₹5.36 crores, which is a 16.8% increase from the previous quarter's ₹4.59 crores but a substantial decrease of 60.6% from ₹13.59 crores in Q3FY24. The earnings per share (EPS) in Q3FY25 was ₹1.00, a 25.0% increase from ₹0.80 in Q2FY25, but a notable decrease of 92.4% from ₹13.20 in Q3FY24.
In Q3FY25, Balaxi Pharmaceuticals Ltd incurred total expenses amounting to ₹71.16 crores, which is a 5.1% increase from ₹67.70 crores in Q2FY25. When compared to Q3FY24, there is a significant rise of 48.2% from ₹48.02 crores. The tax expense for Q3FY25 was ₹0.71 crores, representing a decrease of 26.8% QoQ from ₹0.97 crores in Q2FY25, and a slight increase of 4.4% YoY from ₹0.68 crores in Q3FY24. These metrics show a trend of increasing operational costs over the quarters and years, impacting the company's profitability metrics.